New cancer combo aims to spare patients harsh radiation
NCT ID NCT03174275
Summary
This study is testing a three-step treatment for people with advanced head and neck cancer that can be removed by surgery. First, patients receive a combination of three drugs (carboplatin, nab-paclitaxel, and durvalumab) to try to shrink the cancer. Then, they have surgery. Finally, they receive additional therapy tailored to their specific risk level after surgery, with the goal of avoiding standard radiation treatment and its difficult side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill
Chapel Hill, North Carolina, 27599, United States
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States
Conditions
Explore the condition pages connected to this study.